In 2013, BIO and ViS launched this initiative to improve the efficiency of clinical development for pediatric therapeutics. BIO and its member companies work with ViS to use
The Phase III clinical trial data from the ongoing HPV 070 (NCT01381575) study show that immunogenicity of two doses of Cervarix given at months 0 and 12 is
The collaboration will focus upon developing organs for human patients in need of transplantation, with an initial focus on lung diseases. As part of the agreement SGI will
This agreement was secured in anticipation of Boston Therapeutics’ anticipated IND filing in late 2014, as well as the company’s planned international Phase III trial for BTI-320 that
In addition to accessing the drug via specialty distribution, Eli Lilly made the decision to offer physicians and healthcare practices the opportunity to order CYRAMZA through Biologics as
New pre-clinical data were presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW), held 3 May to 6 May 2014 in Chicago, Illinois. ALN-AAT is one
The investment, which will increase site capacity by more than 20%, comes two years after the company expanded the capacity of its MDI facility in Northridge, California, and
Selexys develops drugs that target certain underlying mechanisms of inflammatory diseases and cancer. SELK2 is an investigational humanized monoclonal antibody designed to treat Crohn’s Disease and Multiple Myeloma.
Abilify Maintena is the first product in Canada from the global alliance between Otsuka and Lundbeck, which is focused on developing central nervous system (CNS) therapies worldwide. Abilify
NanoAntibiotics president and director Rajah Menon noted that the company is excited to be making its debut in the public marketplace and committed to providing its investors with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.